Previous reports have found that 17% of hospitalized COVID-19 patients experience blood clots, says first author Maya Chilbert, PharmD, University at Buffalo clinical assistant professor.
The authors analyzed the outcome of blood clot treatments and the rate of bleeding events for more than 150 patients with COVID-19 who received either of two blood thinner regimens: a full-dose based on patient levels of D-dimer (a protein present in the blood after a blood clot dissolves), and the other a smaller but higher-than-standard dosage.
The average patient age was 58, and all experienced elevated levels of D-dimer, fibrinogen (a protein that helps the body form blood clots), and prothrombin time (a test that measures the time it takes for blood plasma to clot).
Nearly 14% of patients who received full-dose blood thinners experienced a significant bleeding event, compared to only 3% of patients who received a higher-than-standard dosage. All patients who experienced bleeding events were mechanically ventilated. No difference was reported in the regimens’ effectiveness at treating blood clots.
- Dabigatran Blood Thinning Drug Is Safer Than Rat Poison- Study
- Heparin Ineffective At Preventing Blood Clots In Pregnant Women
- Not Supplemental: Omega-3 Fatty Acids Make No Difference In COVID-19
- Felbamate- A Review Of An Amazing But Potentially Dangerous Anti-epileptic
- Quick Positive Results For RNA-Based Pfizer And BioNTech CoVID-19 Vaccine Doesn't Mean It Was Rushed